Abstract
Peripheral arterial disease (PAD) is a common but under-recognized problem. Intermittent claudication is the most frequent symptom of PAD, although the diagnosis of PAD is often overlooked until the patient is presented with limb-threatening ischemia. Importantly, PAD is a marker of generalized atherosclerosis and is closely associated with coronary and cerebrovascular disease. The primary causes of death in patients with PAD are myocardial infarction and stroke. Reducing risk factors is an integral and aggressive part of the treatment regimen. The recognition and diagnosis of PAD, combined with its appropriate medical management, may well reduce the overall risk of cardiovascular morbidity. When diagnosed early, both exercise and pharmacotherapy can ameliorate symptoms of claudication, augment functional performance, and improve quality of life. This review focuses on the general medical management and specific therapeutic options. Because PAD is a manifestation of generalized atherosclerosis, the principal issue in medical management of PAD is a treatment plan that modifies known risk factors for atherosclerosis and its atherothrombotic complications. All patients with PAD should be receiving antiplatelet therapy to prevent ischemic events and ACE inhibitors should be used if appropriate. Medical treatment for patients with claudication includes exercise in rehabilitation and drug therapy. It is also recognized that selected patients with claudication symptoms may benefit from catheter-based interventions, and most PAD patients with critical leg ischemia require revascularization procedures. Although many therapies for claudication have been thoroughly investigated, research continues on new treatments. In contrast, more prospective, randomized trials are needed to evaluate various therapies for treating patients with PAD.
Keywords: peripheral vascular disease, therapy, chronic arterial disease, critical limb ischemia
Current Vascular Pharmacology
Title: Treatment of Chronic Peripheral Arterial Disease
Volume: 1 Issue: 2
Author(s): P. L. Antignani
Affiliation:
Keywords: peripheral vascular disease, therapy, chronic arterial disease, critical limb ischemia
Abstract: Peripheral arterial disease (PAD) is a common but under-recognized problem. Intermittent claudication is the most frequent symptom of PAD, although the diagnosis of PAD is often overlooked until the patient is presented with limb-threatening ischemia. Importantly, PAD is a marker of generalized atherosclerosis and is closely associated with coronary and cerebrovascular disease. The primary causes of death in patients with PAD are myocardial infarction and stroke. Reducing risk factors is an integral and aggressive part of the treatment regimen. The recognition and diagnosis of PAD, combined with its appropriate medical management, may well reduce the overall risk of cardiovascular morbidity. When diagnosed early, both exercise and pharmacotherapy can ameliorate symptoms of claudication, augment functional performance, and improve quality of life. This review focuses on the general medical management and specific therapeutic options. Because PAD is a manifestation of generalized atherosclerosis, the principal issue in medical management of PAD is a treatment plan that modifies known risk factors for atherosclerosis and its atherothrombotic complications. All patients with PAD should be receiving antiplatelet therapy to prevent ischemic events and ACE inhibitors should be used if appropriate. Medical treatment for patients with claudication includes exercise in rehabilitation and drug therapy. It is also recognized that selected patients with claudication symptoms may benefit from catheter-based interventions, and most PAD patients with critical leg ischemia require revascularization procedures. Although many therapies for claudication have been thoroughly investigated, research continues on new treatments. In contrast, more prospective, randomized trials are needed to evaluate various therapies for treating patients with PAD.
Export Options
About this article
Cite this article as:
Antignani L. P., Treatment of Chronic Peripheral Arterial Disease, Current Vascular Pharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570161033476691
| DOI https://dx.doi.org/10.2174/1570161033476691 |
Print ISSN 1570-1611 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Treatment of Cardiovascular Disease in Chronic and End Stage Kidney Disease
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?
Current Cardiology Reviews A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Effectiveness of Psychoeducational Interventions for Improving Symptoms, Health-Related Quality of Life, and Psychological well Being in Patients with Stable Angina
Current Cardiology Reviews Necroptosis: Who Knew There were so Many Interesting Ways to Die?
CNS & Neurological Disorders - Drug Targets Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Editorial [Hot Topic Cells, Micro- and Nanosystems in Reconstructive Medicine: Past, Present, and Future Guest Editors: Christian Andressen & Andreas Wree]
Current Pharmaceutical Biotechnology Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science Coronary Risk Factors in the Elderly: Their Interactions and Treatment
Current Pharmaceutical Design New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Agents in Medicinal Chemistry Cellular Therapy for Myocardial Repair
Current Cardiology Reviews





